129 citations,
February 2006 in “Andrology” Men with low testosterone should be carefully evaluated and monitored before and during treatment.
101 citations,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
February 2012 in “Expert Review of Endocrinology & Metabolism” The document suggests more research is needed to understand the link between baldness and prostate cancer.
September 2010 in “European Urology Supplements” Serum triglyceride levels are not linked to prostate cancer risk.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
7 citations,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
49 citations,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
9 citations,
September 2010 in “Dermatologic Therapy” Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.
4 citations,
November 2005 in “The Journal of Urology” Large prostates link to more hair loss.
3 citations,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
1 citations,
January 2020 in “Skin appendage disorders” Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.
1 citations,
January 2019 in “PubMed” Baldness score can't be used to predict prostate size.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
6 citations,
October 2007 in “Medical Hypotheses” Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.
4 citations,
March 2018 in “Journal of labelled compounds & radiopharmaceuticals” A new compound was effective for imaging prostate cancer in rats.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
November 2012 in “The Journal of Urology” Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
72 citations,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
71 citations,
September 2007 in “Cancer” Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
56 citations,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
28 citations,
June 2010 in “European Journal of Cancer” Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.
28 citations,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.
21 citations,
March 2013 in “Cancer Epidemiology, Biomarkers & Prevention” Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.
18 citations,
March 2009 in “Medical Hypotheses” The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
17 citations,
February 2013 in “Cancer Epidemiology, Biomarkers & Prevention” Early balding at 40 increases prostate cancer risk.